Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Echols

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Biochemical Pharmacology|January 18, 2006
Redefining penemsAxel Dalhoff, Nebojsa Janjic, Roger Echols
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore CephalosporinTakayuki Katsube, Roger Echols, Toshihiro Wajima
Clinical Drug Investigation|May 26, 2021
Comment on 'Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety'Andrew Koren, Andreas Karas, Roger Echols
Frontiers in Pharmacology|March 6, 2023
Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality checkMarkus Zeitlinger, Glenn Tillotson, Roger Echols
The Lancet. Infectious Diseases|December 28, 2018
Cefiderocol for treatment of complicated urinary tract infectionsSimon Portsmouth, Roger Echols, Tsutae Den Nagata
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem ResistanceRoger Echols, Mari Ariyasu, Tsutae Den Nagata
Antimicrobial Agents and Chemotherapy|October 18, 2017
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated PyelonephritisNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
Antimicrobial Agents and Chemotherapy|December 1, 2020
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract InfectionNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
Open Forum Infectious Diseases|March 19, 2021
Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical TrialsSimon Portsmouth, Almasa Bass, Roger Echols, et al.
Nature Biotechnology|December 13, 2006
Moving goalposts--regulatory oversight of antibacterial drugsRandall Brenner, Evelyn J Ellis-Grosse, Roger Echols
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Biochemical Pharmacology|January 18, 2006
Redefining penemsAxel Dalhoff, Nebojsa Janjic, Roger Echols
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore CephalosporinTakayuki Katsube, Roger Echols, Toshihiro Wajima
Clinical Drug Investigation|May 26, 2021
Comment on 'Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety'Andrew Koren, Andreas Karas, Roger Echols
Frontiers in Pharmacology|March 6, 2023
Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality checkMarkus Zeitlinger, Glenn Tillotson, Roger Echols
The Lancet. Infectious Diseases|December 28, 2018
Cefiderocol for treatment of complicated urinary tract infectionsSimon Portsmouth, Roger Echols, Tsutae Den Nagata
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem ResistanceRoger Echols, Mari Ariyasu, Tsutae Den Nagata
Antimicrobial Agents and Chemotherapy|October 18, 2017
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated PyelonephritisNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
Antimicrobial Agents and Chemotherapy|December 1, 2020
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract InfectionNao Kawaguchi, Takayuki Katsube, Roger Echols, et al.
Open Forum Infectious Diseases|March 19, 2021
Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical TrialsSimon Portsmouth, Almasa Bass, Roger Echols, et al.
Nature Biotechnology|December 13, 2006
Moving goalposts--regulatory oversight of antibacterial drugsRandall Brenner, Evelyn J Ellis-Grosse, Roger Echols
Pageof 6